Details of the Drug-Related molecule(s) Interaction Atlas

AGGGWZCOULSEER-PYUWXLGESA-N Drug Info

CHEMBL1922121; SCHEMBL3858001; AGGGWZCOULSEER-PYUWXLGESA-N; BDBM50358222; (3RS,4R)-4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol; US8846696, (3RS,4R)-4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol; (3RS, 4R)-4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol

Cross-matching ID

PubChem CID

12111411

TTD Drug ID

DM2L83Y

General Information of Drug (ID: DM2L83Y)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Patented Agent(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting PRKACA messenger RNA (PRKACA mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VFEDEOUBYBLDKN-AAFJCEBUSA-N	DMH9ION	N. A.	N. A.	Patented	[1]
XHPNYYOUZWOWNT-PYUWXLGESA-N	DM5Q93Y	N. A.	N. A.	Patented	[1]
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[2]
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	DMSKJ1X	Discovery agent	N.A.	Investigative	[3]
Ro-4396686	DM5DMCH	Discovery agent	N.A.	Investigative	[4]
NM-PP1	DMS8H5Q	Discovery agent	N.A.	Investigative	[5]
ISIS 102633	DMWT7BK	Discovery agent	N.A.	Investigative	[6]
ISIS 102604	DMZ6X9B	Discovery agent	N.A.	Investigative	[6]
ISIS 102619	DMXH9IT	Discovery agent	N.A.	Investigative	[6]
ISIS 102462	DMXNC0B	Discovery agent	N.A.	Investigative	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
PRKACA messenger RNA (PRKACA mRNA)	TT5U49F	KAPCA_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Purine derivatives. US8846696.
2	Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry. J Med Chem. 2005 Sep 8;48(18):5613-38. Address;
3	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
4	Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
5	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
6	US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.